Roche (USOTC:RHHBY) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gazyva/Gazyvaro (obinutuzumab) as an additional treatment for adults with moderate-to-severe, active, autoantibody-positive systemic lupus erythematosus (SLE) whose disease remains active despite standard therapy.
The recommendation represents a regulatory step toward potential European Union approval for the treatment. The European Commission is expected to issue a final decision following its review of the committee’s opinion.
The positive recommendation is supported by results from the Phase III ALLEGORY clinical trial, which evaluated Gazyva/Gazyvaro in combination with standard therapy against placebo plus standard therapy.
Phase III ALLEGORY Trial Meets Primary Endpoint
The ALLEGORY study demonstrated a higher treatment response rate among patients receiving Gazyva/Gazyvaro alongside standard therapy compared with those receiving placebo and standard therapy.
At 52 weeks, 76.7% of patients treated with Gazyva/Gazyvaro achieved an improvement of at least four points on the SLE Responder Index (SRI-4), compared with 53.5% of patients in the placebo group.
The SRI-4 measure is used in clinical studies to assess changes in disease activity among patients with systemic lupus erythematosus.
According to Roche, the treatment also demonstrated superiority across all key secondary endpoints evaluated in the study.
These included sustained reductions in glucocorticoid use, sustained SRI-4 response and time to the first disease flare.
Glucocorticoids are commonly used to manage inflammation associated with lupus, although prolonged treatment can be associated with adverse effects.
The trial also reported higher remission rates among patients receiving Gazyva/Gazyvaro.
At the assessed time point, 33.8% of patients in the treatment group achieved remission, compared with 13.8% of those receiving placebo.
The results indicated a difference in remission rates of 20 percentage points between the two groups.
Roche Highlights Need for Additional Lupus Treatments
Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system attacks healthy tissues, potentially affecting multiple organs and causing recurring periods of increased disease activity.
The condition affects an estimated three million people worldwide, including up to 270,000 people in Europe.
Patients may experience recurring disease flares and complications involving the kidneys and other organs.
Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, commented on the clinical needs of patients living with the condition.
“Many people with systemic lupus erythematosus experience recurring flares, progressive organ damage, and chronic steroid dependence,” Garraway said.
“This positive CHMP recommendation brings Gazyva/Gazyvaro a step closer to offering people with SLE a new option that may achieve meaningful and sustained disease control.”
The proposed indication would allow Gazyva/Gazyvaro to be used alongside existing standard treatments in eligible adult patients, subject to approval by the European Commission.
Regulatory Review Also Underway in the United States
Roche is also pursuing regulatory approval for Gazyva/Gazyvaro in systemic lupus erythematosus in the United States.
Earlier in 2026, the US Food and Drug Administration accepted the company’s supplemental Biologics License Application for the proposed indication.
The application is undergoing regulatory review, with no final approval decision for systemic lupus erythematosus reported in the announcement.
Gazyva/Gazyvaro has already received regulatory approval for active lupus nephritis in more than 65 countries.
Lupus nephritis is a kidney complication associated with systemic lupus erythematosus.
The treatment has also received approval in the United States for idiopathic nephrotic syndrome, a condition affecting kidney function.
These existing approvals are separate from the proposed broader indication for systemic lupus erythematosus currently under review.
European Commission Decision Expected
The CHMP recommendation will now be considered by the European Commission, which is responsible for issuing the final marketing authorisation decision for the proposed indication in the European Union.
If approved, Gazyva/Gazyvaro would become an additional treatment option for eligible adults with moderate-to-severe, active, autoantibody-positive systemic lupus erythematosus whose disease remains active despite standard therapy.
The recommendation follows the ALLEGORY trial findings showing higher SRI-4 response and remission rates, together with improvements across the study’s key secondary endpoints.
Roche’s ongoing regulatory reviews in Europe and the United States represent the next stages in its efforts to expand the approved uses of Gazyva/Gazyvaro.
